DZ2522A1 - Composition comprenant un sensibilisant à l'insuline et secrétagogue d'insuline pour une méthode de traitement. - Google Patents

Composition comprenant un sensibilisant à l'insuline et secrétagogue d'insuline pour une méthode de traitement.

Info

Publication number
DZ2522A1
DZ2522A1 DZ980132A DZ980132A DZ2522A1 DZ 2522 A1 DZ2522 A1 DZ 2522A1 DZ 980132 A DZ980132 A DZ 980132A DZ 980132 A DZ980132 A DZ 980132A DZ 2522 A1 DZ2522 A1 DZ 2522A1
Authority
DZ
Algeria
Prior art keywords
insulin
treatment
composition
secretagogue
sensitizer
Prior art date
Application number
DZ980132A
Other languages
English (en)
French (fr)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2522(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712854.0A external-priority patent/GB9712854D0/en
Priority claimed from GBGB9806710.1A external-priority patent/GB9806710D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2522A1 publication Critical patent/DZ2522A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DZ980132A 1997-06-18 1998-06-17 Composition comprenant un sensibilisant à l'insuline et secrétagogue d'insuline pour une méthode de traitement. DZ2522A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712854.0A GB9712854D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806710.1A GB9806710D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
DZ2522A1 true DZ2522A1 (fr) 2003-02-01

Family

ID=26311744

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980132A DZ2522A1 (fr) 1997-06-18 1998-06-17 Composition comprenant un sensibilisant à l'insuline et secrétagogue d'insuline pour une méthode de traitement.

Country Status (34)

Country Link
EP (3) EP0999845B1 (he)
JP (1) JP2001523270A (he)
KR (3) KR20070011651A (he)
CN (1) CN1168451C (he)
AP (1) AP1600A (he)
AR (2) AR012996A1 (he)
AT (1) ATE353654T1 (he)
AU (1) AU8539298A (he)
BG (2) BG64817B1 (he)
BR (1) BR9810142A (he)
CA (1) CA2294385C (he)
CO (1) CO4940457A1 (he)
CZ (1) CZ299310B6 (he)
DE (1) DE69837089T2 (he)
DZ (1) DZ2522A1 (he)
EA (1) EA003025B1 (he)
ES (1) ES2283064T3 (he)
HK (1) HK1028200A1 (he)
ID (1) ID24065A (he)
IL (1) IL133137A (he)
IN (1) IN189319B (he)
MA (1) MA24571A1 (he)
MY (1) MY125855A (he)
NO (3) NO326263B1 (he)
NZ (1) NZ501163A (he)
OA (1) OA11510A (he)
PE (1) PE108199A1 (he)
PL (2) PL198018B1 (he)
SK (1) SK286028B6 (he)
TR (1) TR199903096T2 (he)
TW (1) TW542717B (he)
UA (1) UA67743C2 (he)
UY (1) UY25048A1 (he)
WO (1) WO1998057649A1 (he)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
US7166584B1 (en) 1999-11-01 2007-01-23 Wisconsin Alumni Research Foundation Cholesterol transport gene
WO2002055009A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
KR100698595B1 (ko) * 2003-09-29 2007-03-21 보령제약 주식회사 무정형 또는 준결정형 글리메피리드, 이의 제조방법 및 무정형 또는 준결정형 글리메피리드를 포함하는 약학적조성물
NZ546337A (en) * 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
ES2576258T3 (es) 2005-12-22 2016-07-06 Takeda Pharmaceutical Company Limited Preparación sólida que contiene un sensibilizador de insulina
CN104158867B (zh) * 2014-08-06 2017-05-17 电子科技大学 一种基于wave协议的信息多跳转发方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008651A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1992000967A1 (fr) 1990-07-03 1992-01-23 Yamanouchi Pharmaceutical Co., Ltd. Compose biheterocyclique
EP0544696B1 (en) 1990-08-23 1995-01-11 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
KR100249988B1 (ko) 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
TW222626B (he) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
WO1993021166A1 (en) 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
PL174610B1 (pl) 1992-07-03 1998-08-31 Smithkline Beecham Plc Nowe związki heterocykliczne
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
NO996264L (no) 2000-02-17
CZ299310B6 (cs) 2008-06-18
UY25048A1 (es) 2000-09-29
UA67743C2 (uk) 2004-07-15
BG64817B1 (bg) 2006-05-31
DE69837089D1 (de) 2007-03-29
PE108199A1 (es) 2000-01-14
EA003025B1 (ru) 2002-12-26
CN1168451C (zh) 2004-09-29
TR199903096T2 (xx) 2000-08-21
CN1260719A (zh) 2000-07-19
NZ501163A (en) 2002-02-01
DE69837089T2 (de) 2007-06-21
AP1600A (en) 2006-04-28
ID24065A (id) 2000-07-06
NO2009002I1 (no) 2009-03-02
CA2294385C (en) 2007-06-05
CO4940457A1 (es) 2000-07-24
OA11510A (en) 2004-02-03
PL198018B1 (pl) 2008-05-30
EP2266576A1 (en) 2010-12-29
KR20070011651A (ko) 2007-01-24
ATE353654T1 (de) 2007-03-15
AU8539298A (en) 1999-01-04
KR20010013840A (ko) 2001-02-26
SK179199A3 (en) 2000-11-07
EP1671637A3 (en) 2007-12-19
EP0999845A1 (en) 2000-05-17
TW542717B (en) 2003-07-21
PL337510A1 (en) 2000-08-28
IL133137A (he) 2004-02-08
EA200000039A1 (ru) 2000-08-28
IL133137A0 (en) 2001-03-19
MA24571A1 (fr) 1998-12-31
EP1671637A2 (en) 2006-06-21
HK1028200A1 (en) 2001-02-09
BR9810142A (pt) 2000-08-08
CZ9904577A3 (en) 2001-05-16
IN189319B (he) 2003-02-08
ES2283064T3 (es) 2007-10-16
AR008025A1 (es) 1999-12-09
BG109397A (bg) 2006-05-31
JP2001523270A (ja) 2001-11-20
NO20083276L (no) 2000-02-17
WO1998057649A1 (en) 1998-12-23
AP9901717A0 (en) 1999-12-31
CA2294385A1 (en) 1998-12-23
BG104058A (en) 2000-10-31
NO996264D0 (no) 1999-12-17
AR012996A1 (es) 2000-11-22
MY125855A (en) 2006-08-30
NO326263B1 (no) 2008-10-27
SK286028B6 (sk) 2008-01-07
EP0999845B1 (en) 2007-02-14
KR20080011356A (ko) 2008-02-01

Similar Documents

Publication Publication Date Title
FR2690263B3 (fr) Procédé et appareil de développement d&#39;une forme bidimensionnelle.
DZ2520A1 (fr) Composition pharmaceutique pour une méthode de traitement du diabète sucré.
EP0709769A3 (en) Apparatus and method for analysis and resolution of operand dependencies
EP0619551A3 (en) Determination of the offset between images of an integrated circuit.
DE69834209D1 (de) Bildverarbeitungsverfahren
FR2716989B1 (fr) Procédé de fonctionnement d&#39;une carte à puce.
DZ2522A1 (fr) Composition comprenant un sensibilisant à l&#39;insuline et secrétagogue d&#39;insuline pour une méthode de traitement.
DZ2521A1 (fr) Compositions pharmaceutiques comprenant de la 5-Ä4-Ä2-(méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜ-thiazolidine-2,4-dione et de l&#39;insuline pour une méthode de traitement.
DE69003638D1 (de) Entwickler fuer statische ladungsbilder.
FR2716075B1 (fr) Procédé pour renforcer l&#39;efficacité d&#39;un produit chimique agricole, renforçateur et composition de renforçateur utilisés dans ce procédé et composition chimique agricole comprenant ce renforçateur.
EP1024697A4 (en) METHOD FOR TREATING ALZHEIMER&#39;S DISEASE
DZ2562A1 (fr) Composition contenant un sensibilisant à l&#39;insuline un secrétagogue d&#39;insuline et un biguanide anti-hyperglycémique.
FR2643474B1 (fr) Dispositif pour enregistrer un historique d&#39;execution dans une unite de traitement de l&#39;information
FR2720843B1 (fr) Toner pour développer des images de charges statiques, et procédé pour le préparer.
DZ2519A1 (fr) Compositions pharmaceutiques comprenant un sensibilisant à l&#39;insuline et un agent antihyperglycémique pour une méthode de traitement du diabéte.
FR2766044B1 (fr) Procede de traitement d&#39;une sequence d&#39;images radiologiques d&#39;un objet
DZ2563A1 (fr) Composition contenant un sensibilisant à l&#39;insuline un secrétagogue d&#39;insuline et un biguanide anti-hyperglycérnique inhibiteur d&#39;alpha-glucosidase.
FR2691814B1 (fr) Procédé et appareillage d&#39;impression d&#39;une image.
ITTO910003A0 (it) Composizione metallica per riporto e metodo per il suo impiego.
FR2661341B2 (fr) Dispositif pour fixer des elements d&#39;outils de presse dans leur support.
FR2693615B1 (fr) Procédé d&#39;identification d&#39;objets dans une image.
ITRM940776A0 (it) Apparecchio di formazione di immagini per rivelare otticamente la quantita&#39; di un agente di sviluppo
AU123249S (en) Developing processor for image formation
ITMI930448A1 (it) Procedimento per trattare un&#39;immagine di una frazione nell&#39;elettroforesi.
FR2772946B1 (fr) Procede de determination d&#39;un depassement de format du resultat d&#39;une operation arithmetique realisee sur deux operandes